

PATENT Customer No. 22,852 Attorney Docket No. 02481.1655-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Ursula SCHINDLER et al.) Group Art Unit: To Be Assigned
Application No.: To Be Assigned (Divisional of Application No. 09/497,723))) Examiner: S. PATEL)
Filed: October 1, 2003	
For: SUBSTITUTED 4-AMINO-2-ARYL- TETRAHYDROQUINAZOLINES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM))))
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
Sir:	


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application.

Copies of the listed documents were previously submitted or cited in a prior application, Application No. 09/497,723, filed on February 4, 2000, upon which Applicants rely for the benefits provided in 35 U.S.C. § 120. Applicants respectfully

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com





request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: October 1, 2003

By: Rea No 51,688

Anthony C. Tridico Reg. No. 45,958

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	2481.1655-01	Appln. No.	To Be Assigned (Divisional of Application No. 09/497,723)
Applicant	Ursula SCHINDLER et al.		
Filing Dațe	October 1, 2003	Group:	To Be Assigned

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	4,306,065	12/15/81	Chen			
	3,322,759	05/30/67	Carney et al.	· ·		
	3,346,452	10/10/67	Carney et al.			
	6,245,760	06/12/01	He et al.			
	4,610,984	09/09/86	Schonafinger et al.			
	5,250,530	10/05/93	Giencke et al. (English equivalent of EP 0 407 899)			

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	EP 0 579 496	01/19/94	EPO			
	WO 00/48214	08/10/00	PCT			
	DE 40 29 654 A1	04/02/92	Germany			Abstract in English
	EP 0 667 345 A1	08/16/95	EPO			
	JP 7-228573	08/29/95	Japan			Abstract in English
	EP 0 826 673 A1	03/04/98	EPO			
	WO 97/47601	12/18/97	PCT			Abstract in English
	WO 98/16223	04/23/98	PCT			Abstract in English
	WO 98/16507	04/23/98	PCT			Abstract in English
	WO 96/32383	10/1996	PCT			Abstract in English
	EP 0 407 899	07/24/91	EPO			English equivalent 5,250,530
	WO 00/31047	06/02/00	PCT			Abstract in English
	WO 00/09496	02/24/00	PCT		*	Abstract in English
	JP 10-130150	05/19/98	Japan			Abstract in English



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	2481.1655-01	Appln. No.	To Be Assigned (Divisional of Application No. 09/497,723)
Applicant	Ursula SCHINDLER et al.		7
Filing Date	October 1, 2003	Group:	To Be Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
 Abstract: DE 40 29 654 A1 - P. Braun, K. Minn, B. Sachse, and H. Wicke, "New 2-phenyl-pyrimidine derivations - useful as plant protectants, especially fungicides," Derwent Abstract No. 92-115248/199215.
Abstract: 07-228573 - Yoshiaki Ochi, "2-Phenylcycloalkanopyrimidine Derivative," European Pater Office Abstract.
 Louis J. Ignarro, "Regulation of Cytosolic Guanylyl Cyclase by Porphyrins and Metalloporphyrins," <i>Advances in Pharmacology</i> , Volume 26: 35-65 (1994).
 Feng-Nien Ko, Chin-Chung Wu, Sheng-Chu Kuo, Fang-Yu Lee, and Che-Ming Teng, "YC-1, a Novel Activator of Platelet Guanylate Cyclase," <i>Blood,</i> Volume 84 (12), 4226-4233 (December 15, 1994).
 Douglas J. Pettibone, Charles S. Sweet, Edwin A. Risley and Thomas Kennedy, "A Structurally Novel Stimulator of Guanylate Cyclase with Long-Lasting Hypotensive Activity in the Dog," <i>European Journal of Pharmacology</i> , Volume 116: 307-312 (1985).
D. L. Vesely, "B complex vitamins activate rat guanylate cyclase and increase cyclic GMP levels," European Journal of Clinical Investigation, Volume 15: 258-262 (1985).
David L. Vesely, "Phencyclidine Stimulates Guanylate Cyclase Activity," <i>Biochemical and Biophysical Research Communications</i> , Volume 88(4): 1244-1248 (June 27, 1979).
Chin-Chung Wu, Feng-Nien Ko, Sheng-Chu Kuo, Fang-Yu Lee, and Che-Ming Teng, "YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase," <i>British Journal of Pharmacology</i> , Volume 116: 1973-1978 (1995).
 Sheu-Meei Yu and Sheng-Chu Kuo, "Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta," <i>British Journal of Pharmacology,</i> Volume 114: 1587-1594 (1995).
Sheu M. Yu, Zhi J. Chen, Jih H. Guh, Fang Y. Lee, and Sheng C. Kuo, "Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells," <i>Biochem J.</i> , Volume 306: 787-792 (1995).
Abstract: JP 07 228573 A - Masahiro Kataoka, Katsuhiko Hino, and Yoshiaki Ochi, "Preparation of 2-phenylcycloalkanopyrimidine derivatives as antagonists of serotonin 8, receptor," <i>Chemical Abstracts</i> , Columbus, Ohio, Vol. 124, 87634q, 1996.
Abstract: JP 10 130150 A - Akiya Murata, Katsuhiko Hino, Kiyoshi Furukawa, Makoto Oka, and Mari Ito, "Preparation of acetic acid amide derivatives as drugs," <i>Chemical Abstracts</i> , Columbus, Ohio, Vol. 129, 54385e, 1998.



INFORMATION DISCLOSURE CITATION

Atty. Docket No.	2481.1655-01	Appln. No.	To Be Assigned (Divisional of Application No. 09/497,723)
Applicant	Ursula SCHINDLER et al.		
Filing Date	October 1, 2003	Group:	To Be Assigned

International Search Report mailed May 29, 2000.
 Abstract: Honda, I. et al., "Synthesis and Dimroth Rearrangement of 2,4-bis(2-hydroxy-1-cycloalkenyl)-1,3,5-triazines," Fukui Daigaku Kogakubu Kenkyu Hokoku 36/2, 165-81 (1988).
Liddendirff et al., "Multiple Roles of the Messenger Molecule cGMP in Testicular Function," Andrologia, 32/1, 55-59 (2000).

Examiner		Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		MINORMATICE and not considered. Include copy of this form with most
Form PTO 14	49	Patent and Trademark Office - U.S. Department of Commerce